Related Experiment Video
Updated: Jul 4, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Etiology, pathophysiology, and treatment of atrial fibrillation: part 1
1Department of Medicine, Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA. wsaronow@aol.com
Insights
Atrial fibrillation (AF) increases risks for stroke and death. Immediate treatment is crucial for patients with AF experiencing acute symptoms like chest pain or heart failure, with cardioversion or medications like beta blockers being key interventions.
Area of Science:
- Cardiology
- Electrophysiology
- Internal Medicine
Background:
- Atrial fibrillation (AF) is linked to increased mortality, stroke, and coronary events compared to sinus rhythm.
- Rapid ventricular rates in AF can precipitate tachycardia-related cardiomyopathy.
- Effective management of AF is critical for patient outcomes.
Purpose of the Study:
- To review the etiology, pathophysiology, and treatment of atrial fibrillation (AF).
- To outline immediate management strategies for AF patients with acute symptoms.
- To discuss pharmacological and non-pharmacological treatment options for rate control in AF.
Main Methods:
- Review of current medical literature on atrial fibrillation management.
- Analysis of treatment guidelines for acute and chronic AF.
- Discussion of drug classes including beta blockers, calcium channel blockers, amiodarone, and digoxin.
Main Results:
- Immediate direct-current cardioversion is recommended for AF patients with acute myocardial infarction, ischemia, hypotension, severe heart failure, or syncope.
- Intravenous beta blockers, verapamil, or diltiazem are effective for rapid rate control in acute AF.
- Oral agents or non-pharmacologic therapies are indicated for persistent or drug-refractory AF rate control.
Conclusions:
- Timely intervention with cardioversion or medications is vital for hemodynamically unstable AF patients.
- A stepwise approach to rate control, utilizing various pharmacological and non-pharmacological options, is essential for managing AF.
- Digoxin is not recommended for paroxysmal AF, and amiodarone is reserved for refractory cases.
Abstract:
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nonpharmacologic therapies should be used in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. This is part 1 of a 2-part review of the etiology, pathophysiology, and treatment of atrial fibrillation. The second part will be published in the subsequent issue of Cardiology in Review.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias
Mechanism of Cardiac Arrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
Aortic Regurgitation I: Introduction

